This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ChinaBio® Partnering Forum
The Kerry Hotel
September 10–11, 2024 | Shanghai, ChinaSeptember 16–17, 2024 | Virtual

John Zhu
Founder & CEO at Duality Biologics


Dr. John Zhu founded Duality Biologics in 2020. He has served as CEO and Chairman of the Board from the company’s start. He has over 20 years of leadership in venture investment and biotech entrepreneurship. Previously, he served as the partner of 6 Dimensions Capital and Wuxi Ventures, investing and incubating many leading biotechs including CStone, Remegen, Ganlee Pharma and BGI etc.

Dr. John Zhu received his Ph.D. from University of Massachusetts Medical School and an MBA from the University of California, Berkeley.

DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced 4 assets into global clinical studies, and developed more than 10 innovative product candidates which are currently in preclinical stage. Additionally, DualityBio is continuing evolving its novel protein engineering and ADC technology platforms for the next wave of “super ADC” molecules including diverse payload classes, bispecific ADCs and dual payload ADCs.

Agenda Sessions

  • Panel: CEO Perspective on the state of innovation in China - identifying the drivers, opportunities and challenges ahead.


At this event